Skip to main content

Table 2 Characteristics of patients without diabetes according to concomitant events.

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

  1. No-diabetes w/o event 2. No-diabetes with event
NHIS NHIS + Eze HIS HIS + Eze p value* NHIS NHIS + Eze HIS HIS + Eze p value*
Nr. patients 16,131 (85) 1305 (7) 1492 (8) 123 (1)   3946 (47) 738 (9) 3265 (39) 374 (5)  
Adherent 12,586 (78) 1091 (84) 1213 (81) 112 (91) < 0.001 3186 (81) 660 (89) 2767 (85) 356 (95) < 0.001
Total-chol (mg/dl)a 180.3 (37) 178.5 (43) 168.7 (43) 170.1 (46) < 0.001 152.6 (39) 150.2 (36) 139.1 (33) 136.6 (33) < 0.001
LDL-chol (mg/dl)a 103.8 (31) 100.8 (36) 95.6 (36) 100 (42) < 0.001 84.5 (31) 79.5 (28) 75.4 (27) 72.7 (26) < 0.001
HDL-chol (mg/dl)a 56.2 (16) 55.6 (15) 52.7 (16) 52.5 (14) < 0.001 49 (16) 50.6 (15) 46.5 (14) 47.2 (13) < 0.001
Triglycerides (mg/dl)a 97.6 (58) 102.9 (65) 97.2 (66) 85.1 (47) 0.001 86.4 (59) 92.4 (65) 78.7 (54) 74 (48) < 0.001
NON-HDL-chol (mg/dl)a 124.1 (34) 122.8 (42) 116 (40) 117.6 (45) < 0.001 103.6 (35) 99.6 (33) 92.6 (30) 89.4 (31) < 0.001
GFR (ml/min/1.73 m2)a 91.8 (26) 89.6 (25) 95.2 (31) 93.4 (44) < 0.001 80.4 (34) 80.3 (30) 89.6 (30) 92.3 (23) < 0.001
HbA1c (mmol/mol)a 41 (8) 40.8 (6) 41.3 (7) 40.7 (6) N.S 40 (7) 39.7 (5) 39.6 (6) 40.6 (8) N.S
CHD       1672 (42) 398 (54) 1197 (37) 215 (58) < 0.001
Cerebrovascular disease       1565 (40) 171 (23) 1307 (40) 44 (12) < 0.001
PAD       4 (0) N.I N.I 0 (0) N.S
ACEi/ARB 9001 (56) 710 (54) 906 (61) 77 (63) 0.001 2608 (66) 520 (71) 2269 (70) 278 (74) < 0.001
Beta blockers 4178 (26) 359 (28) 539 (36) 51 (42) < 0.001 2041 (52) 491 (67) 1914 (59) 277 (74) < 0.001
CCB 3183 (20) 248 (19) 296 (20) 16 (13) N.S 1096 (28) 183 (25) 782 (24) 72 (19) < 0.001
Fibrates 83 (1) 7 (1) 12 (1) N.I N.S 16 (0) 7 (1) 9 (0) N.I N.S
  1. Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. CHD coronary heart disease, PAD peripheral artery disease, ACEi angiotensin converting-enzyme inhibitors, ARBs angiotensin II receptor blocker, CCB calcium channel blockers
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index